JSS Stock Overview
Develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Nxera Pharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥6.85 |
| 52 Week High | JP¥11.80 |
| 52 Week Low | JP¥6.60 |
| Beta | 0.63 |
| 11 Month Change | 0% |
| 3 Month Change | -34.13% |
| 1 Year Change | -21.26% |
| 33 Year Change | -59.71% |
| 5 Year Change | -63.02% |
| Change since IPO | -15.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| JSS | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.4% | -1.2% | -0.02% |
| 1Y | -21.3% | -20.1% | 8.2% |
Return vs Industry: JSS underperformed the German Pharmaceuticals industry which returned -20.1% over the past year.
Return vs Market: JSS underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| JSS volatility | |
|---|---|
| JSS Average Weekly Movement | 6.3% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: JSS has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: JSS's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 372 | Chris Cargill | www.nxera.life |
Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company’s development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders.
Nxera Pharma Co., Ltd. Fundamentals Summary
| JSS fundamental statistics | |
|---|---|
| Market cap | €631.15m |
| Earnings (TTM) | -€23.02m |
| Revenue (TTM) | €181.56m |
3.5x
P/S Ratio-27.4x
P/E RatioIs JSS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JSS income statement (TTM) | |
|---|---|
| Revenue | JP¥29.28b |
| Cost of Revenue | JP¥5.43b |
| Gross Profit | JP¥23.85b |
| Other Expenses | JP¥27.56b |
| Earnings | -JP¥3.71b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -41.28 |
| Gross Margin | 81.46% |
| Net Profit Margin | -12.68% |
| Debt/Equity Ratio | 95.8% |
How did JSS perform over the long term?
See historical performance and comparison